Abbott’s MitraClip system shows favorable outcome in treating people with Mitral Regurgitation

The study analyzed data from the Transcatheter Valve Therapy (TVT) registry involving nearly 3,000 DMR patients who were high-risk for surgery. Following minimally invasive implantation with MitraClip, patients had significant improvements, including 92.8 percent of patients achieving post-procedural mitral regurgitation (MR) severity grade of less than or equal to 2 (acute procedural success defined as MR =2). In addition, 80.0 percent of MitraClip patients remained free from heart failure (HF) re-hospitalization in the year after implantation. Most patients--85.9 percent of people treated--were discharged to their homes after an average hospital stay of only two days. The average age of patients was 82.

The data were presented by Paul Sorajja, M.D., director of the Center of Valve and Structural Heart Disease at Minneapolis Heart Institute, cardiologist at Abbott Northwestern Hospital in Minneapolis and principal investigator of the study, during a late-breaking featured clinical research session of the American College of Cardiology's (ACC) 66th Annual Scientific Session.

"The consistent one-year results seen in this study validate that treatment with MitraClip can provide meaningful reduction in the severity of mitral regurgitation," said Dr. Sorajja. "The consistency of data over time in this large patient registry underscore the valuable impact MitraClip has on the overall health of very sick people living with this silent killer."

Mitral regurgitation is a debilitating, progressive and life-threatening disease in which the leaflets of the mitral valve do not close completely, causing blood to flow backward and leak into the left atrium of the heart during the cardiac cycle. The condition can raise the risk of irregular heartbeats, stroke, and heart failure, which can be deadly.  

Nearly one in ten people over the age of 75 have moderate to severe MR1 , which is frequently difficult to diagnose. Patients often may not be eligible for the standard-of-care surgery because of advanced age, frailty, multiple comorbidities or other complicating factors. Until the regulatory approval of MitraClip, these high surgical risk patients could only manage their symptoms, such as shortness of breath and fatigue, with medications that did not stop the progression of the disease.
The study analyzed data from the Transcatheter Valve Therapy (TVT) registry involving nearly 3,000 DMR patients who were high-risk for surgery. Following minimally invasive implantation with MitraClip, patients had significant improvements, including 92.8 percent of patients achieving post-procedural mitral regurgitation (MR) severity grade of less than or equal to 2 (acute procedural success defined as MR =2). In addition, 80.0 percent of MitraClip patients remained free from heart failure (HF) re-hospitalization in the year after implantation. Most patients--85.9 percent of people treated--were discharged to their homes after an average hospital stay of only two days. The average age of patients was 82.

The data were presented by Paul Sorajja, M.D., director of the Center of Valve and Structural Heart Disease at Minneapolis Heart Institute, cardiologist at Abbott Northwestern Hospital in Minneapolis and principal investigator of the study, during a late-breaking featured clinical research session of the American College of Cardiology's (ACC) 66th Annual Scientific Session.

"The consistent one-year results seen in this study validate that treatment with MitraClip can provide meaningful reduction in the severity of mitral regurgitation," said Dr. Sorajja. "The consistency of data over time in this large patient registry underscore the valuable impact MitraClip has on the overall health of very sick people living with this silent killer."

Mitral regurgitation is a debilitating, progressive and life-threatening disease in which the leaflets of the mitral valve do not close completely, causing blood to flow backward and leak into the left atrium of the heart during the cardiac cycle. The condition can raise the risk of irregular heartbeats, stroke, and heart failure, which can be deadly.  

Nearly one in ten people over the age of 75 have moderate to severe MR1 , which is frequently difficult to diagnose. Patients often may not be eligible for the standard-of-care surgery because of advanced age, frailty, multiple comorbidities or other complicating factors. Until the regulatory approval of MitraClip, these high surgical risk patients could only manage their symptoms, such as shortness of breath and fatigue, with medications that did not stop the progression of the disease.

"Abbott's goal is to improve health, and our MitraClip therapy provides a much-needed solution for gravely ill people who have very few options," said Michael Dale, general manager of Abbott's structural heart business. "The consistency in data across multiple trials reinforce the nearly immediate impact that MitraClip has on people's quality of life, allowing them to lead fuller, longer lives."
"Abbott's goal is to improve health, and our MitraClip therapy provides a much-needed solution for gravely ill people who have very few options," said Michael Dale, general manager of Abbott's structural heart business. "The consistency in data across multiple trials reinforce the nearly immediate impact that MitraClip has on people's quality of life, allowing them to lead fuller, longer lives."

Abbott’s mitraclip system, favorable outcome, treating people with mitral regurgitation